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Influenza A(H1N1)pdm09 viruses predominated in the 
European influenza 2015/16 season. Most analysed 
viruses clustered in a new genetic subclade 6B.1, 
antigenically similar to the northern hemisphere vac-
cine component A/California/7/2009. The predomi-
nant influenza B lineage was Victoria compared with 
Yamagata in the previous season. It remains to be 
evaluated at the end of the season if these changes 
affected the effectiveness of the vaccine for the 
2015/16 season. 
For the current northern hemisphere season, several 
reports have indicated intense influenza activity [1-5]. 
We analysed virological surveillance data from 20 
European countries to study the genetic and antigenic 
characteristics of the circulating influenza viruses and 
compare them with the vaccine viruses and previously 
circulating strains.
Virological influenza surveillance in 
Europe, influenza season 2015/16
Virological influenza surveillance data in the World 
Health Organization (WHO) European Region are col-
lected on a weekly basis and reported to The European 
Surveillance System (TESSy), a database hosted by the 
European Centre for Disease Prevention and Control 
(ECDC), as previously described [6]. From week 40/2015 
to week 4/2016, 49 Member States of the Region 
reported influenza virus detections to TESSy, including 
20 Member States (Belgium, Croatia, Czech Republic, 
Denmark, Finland, Germany, Greece, Ireland, Latvia, 
Netherlands, Norway, Portugal, Romania, Russia, 
Slovakia, Slovenia, Spain, Sweden, Switzerland, and 
the United Kingdom (UK)) that also reported antigenic 
or genetic characterisation data. 
The antigenic and genetic reporting categories for 
TESSy are predefined by the WHO Collaborating Centre 
for Reference and Research on Influenza, London, for 
each influenza season. For antigenic characterisation, 
to denote a virus isolate as being like a vaccine or ref-
erence virus its haemagglutination inhibition (HI) titre 
with post-infection ferret antiserum raised against the 
reference virus should differ by no more than fourfold. 
For genetic characterisation, the allocation to reporting 
category is based on the phylogenetic and amino acid 
sequence analyses of haemagglutinin (HA) gene. 
The summary analysis of the data are presented weekly 
in the Joint ECDC–WHO Regional Office for Europe 
weekly ‘Flu News Europe’ (http://flunewseurope.org/). 
Data on detections, antigenic and genetic characterisa-
tions were extracted on 8 February 2016 for analysis.
Between week 40/2015 and week 4/2016, influenza 
viruses were detected in 1,879 (19%) of 9,882 sentinel 
specimens tested in the 20 countries also reporting 
on virus characterisation. Of these 1,879 specimens, 
1,512 (80%) were positive for type A influenza virus and 
367 (20%) for type B. Of 1,441 subtyped influenza A 
viruses, 1,268 (88%) were A(H1N1)pdm09. Of 129 type 
B viruses with known lineage, 115 (89%) were of the B/
Victoria/2/1987 lineage.
2 www.eurosurveillance.org
Figure 1
Phylogenetic analysis of A(H1N1)pdm09 haemagglutinin (HA) nt sequences reported from European countries, between 
week 40/2015 and 4/2016
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Some sequences obtained in this study were not used to construct the phylogenetic tree because they were identical and redundant. The sequences used for 
the phylogenetic analysis were moreover only those of suitable length, and encode HA1 amino acids 3–327. These included sequences reported by the Czech 
Republic, Finland, Greece, Netherlands, Norway, Portugal, Romania, Russia, Slovenia, Spain and Sweden as well as sequences from reference A(H1N1)pdm09 
viruses. The tree was constructed with the neighbour-joining method, using Kimura-2 parameter-corrected distances and bootstrapped with 1,000 replicates, 
Molecular Evolutionary Genetics Analysis (MEGA) software version 5.0.
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Virus characterisation
Between weeks 40/2015 and 4/2016, 447 (24%) of 1,879 
influenza viruses were attributed to a genetic group 
by 16 countries (Belgium, Czech Republic, Denmark, 
Finland, Germany, Greece, Ireland, Netherlands, 
Norway, Portugal, Romania, Russia, Slovenia, Spain, 
Sweden and UK), and 429 (23%) were attributed to 
an antigenic category by also 16 reporting countries 
(Croatia, Czech Republic, Denmark, Finland, Germany, 
Greece, Latvia, Netherlands, Portugal, Romania, 
Russia, Slovakia, Slovenia, Spain, Switzerland and UK) 
(Table 1).
The majority (68%) of all genetic characterisations 
were reported from Norway (n=84), Spain (n=66), 
Germany (n=54), Russia (n=54) and Sweden (n=46). 
The majority (70%) of antigenic reports were from 
Russia (n=124), Portugal (n=99) and Germany (n=78). 
For 150 viruses, reported in strain-based manner, both 
genetic and antigenic data were available.
All 313 A(H1N1)pdm09 viruses characterised genetically 
fell in clade 6, subgroup 6B, represented by A/South 
Africa/3626/2013. Viruses falling in this genetic sub-
group, were all attributed to an antigenic category A/
California/7/2009 that corresponds to the component 
included in the 2015/16 northern hemisphere vaccines.
Of the 77 A(H3N2) viruses attributed to a genetic 
group, 50 (65%) fell into genetic subgroup 3C.2a 
(represented by A/Hong Kong/4801/2014) that has 
been shown to be antigenically similar to A/Hong 
Kong/4801/2014 and also to the current A(H3N2) vac-
cine virus A/Switzerland/9715293/2013 (Table 1). 
Twenty-six A(H3N2) viruses fell into the vaccine virus 
category of 3C.3a subgroup. Viruses in subgroup 3C.3b 
(represented by A/Stockholm/28/2014) constituted 
a substantial part (98/401) of the A(H3N2) viruses in 
Europe in the 2014/15 season [7], but none were yet 
reported by week 4/2016 (Table 1). Of 20 A(H3N2) 
viruses attributed to an antigenic category, 14 were 
A/Switzerland/9715293/2013-like and thus similar to 
the northern hemisphere 2015/16 vaccine component 
and six were A/Hong Kong/4801/2014-like, similar to 
the southern hemisphere 2016 vaccine component 
and recommendation for northern hemisphere 2016/17 
season.
All of the 44 B/Victoria lineage viruses characterised 
genetically to date fell in the clade 1A, represented by 
B/Brisbane/60/2008 which is included in quadrivalent 
vaccines for northern hemisphere 2015/16. The 13 B/
Yamagata lineage viruses all genetically resembled 
B/Phuket/3073/2013 recommended for inclusion in 
trivalent vaccines for northern hemisphere 2015/16. 
Thirty influenza B viruses were antigenically charac-
terised, 29 as B/Brisbane/60/2008-like and one as B/
Phuket/3073/2013-like.
Analysis of A(H1N1)pdm09 HA gene sequences from 
12 countries (Czech Republic, Finland, Greece, Ireland, 
Netherlands, Norway, Portugal, Romania, Russia, 
Slovenia, Spain and Sweden) reported to TESSy, with 
provision of accession numbers in publicly accessible 
databases, confirmed that all these analysed viruses 
possessed the signature amino acid variations that 
define subgroup 6B viruses: D97N, K163Q, S185T, 
K283E and A256T [7-9]. All 215 analysed sequences, 
apart from two viruses isolated in Russia, also carried 
P83S and I321V substitutions in HA1. 
The majority of sequences (173 of 215 TESSy-reported 
viruses) also possessed the amino acid signature of 
subclade 6B.1 and formed a separate branch in the 
phylogenetic analysis (Figure 1, Figure 2). The 6B.1 sub-
clade is characterised by the amino acid substitutions 
S84N (present in a wider subgroup), S162N and I216T 
[8]. Six viruses carried amino acid substitutions V152T, 
V173I, D501E (the latter in HA2) characterising 6B.2 
subclade. In addition the five most recently sampled of 
these six 6B.2 viruses all possessed the R113K, D127E 
and E374Q substitutions (Figure 1). 
The highest number of accumulated variations in the 
known antigenic sites were observed in the antigenic 
site Ca. All subgroup 6B viruses possessed the K163Q 
substitution, while the vast majority (173/215; 80%) 
also possessed the S162N substitution in HA1, result-
ing in a gain of a potential glycosylation site. Additional 
Figure 2
Protein structure model (FluSurver-JSmol) of the 
haemagglutinin protein monomer of A(H1N1)pdm09 
subclade 6B.1, represented by A/Norway/2650/2015 (left), 
and subclade 6B.2, represented by A/Norway/2658/2015 
(right)
Amino acid differences compared with A/California/07/2009 are 
indicated in colour. Well-known differences are marked in blue. 
Common variant marker positions are indicated in green. Amino 
acid involved in virulence or antigenic drift is marked in orange. 
Amino acid not previously associated with a specific feature 
is marked in grey. Amino acid that creates a new potential 
N-glycosylation site is marked in magenta.
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variations observed were S162K, D168N, K170E, R205K, 
A215G, E235D and a partial A139D. Cb antigenic site 
variation A73S was observed in four viruses from 
Spain, one of which also possessed substitution N156K 
in Sa antigenic site. Another Norwegian virus had a 
N156S substitution in Sa antigenic site. Notably, all 
6B.2 viruses and also two of the 6B viruses not belong-
ing to any of the newly identified subgroups possessed 
substitutions affecting the loop that consists of amino 
acid positions 151 to 159 located adjacent to the recep-
tor binding site.
When comparing the A(H1N1)pdm09 strains with the 
corresponding strain in the current northern hemi-
sphere influenza vaccine, A/California/7/2009, the HA1 
sequences (nt 1–981, amino acids 1–327) exhibited nt 
similarity of 96.8 to 98.0% and deduced amino acid 
similarity of 95.4 to 96.3%. Viruses within subclade 
6B.1 exhibited higher HA nt heterogeneity, with simi-
larities ranging between 98.8 and 100%, while within 
subclade 6B.2 strains exhibited higher nt similarity, 
ranging between 99.3 and 100%, as the group consists 
of fewer sequences and most of them from one region 
only. The viruses analysed phylogenetically are listed 
in Table 2.
Discussion
Continuous surveillance of influenza viruses is essen-
tial for detecting emerging new variant strains and pro-
viding viruses for vaccine production [10]. In Europe, 
within the detected A subtypes, influenza A(H1N1)
pdm09 predominated during 2010/11, 2012/13 and 
2013/14 seasons and concerned 97% [11], 62% [12] and 
53% [13] of subtyped influenza viruses respectively, 
with variation in country-specific proportions. The 
A(H1N1)pdm09 vaccine component A/California/7/2009 
has not been changed since the 2009 pandemic and 
the circulating A(H1N1)pdm09 viruses have remained 
antigenically similar to the virus included in the vac-
cines throughout the influenza 2009/10 to 2015/16 
seasons. However, since 2013, several reports have 
indicated the emergence of an expanding subgroup 
of A(H1N1)pdm09 viruses, designated 6B [1,8,9]. This 
subgroup appeared in 2012/13 and became predomi-
nant in 2013/14 [14].
In this study, we observe the further emergence of a 
subclade within the 6B subgroup, designated 6B.1 [15], 
which accounted for the majority of the A(H1N1)pdm09 
viruses detected across the WHO European Region dur-
ing the first weeks of the 2015/16 influenza season. In 
addition, the surveillance data show a change in the 
predominant B virus lineage from B/Yamagata which 
predominated in the preceding three seasons in Europe 
to B/Victoria.
Our data are preliminary for this season and are based 
on influenza surveillance without detailed reporting of 
clinical symptoms or vaccination status. Our genetic 
analysis was only based on the HA gene and does not 
extend to changes e.g. in genes encoding internal pro-
teins of influenza viruses. The data reported to TESSy 
do not include antigenic titres and therefore no direct 
analysis of antigenic properties was possible. However, 
the antigenic reports rely on national influenza centres’ 
antigenic analysis that the viruses reported as like to 
vaccine virus were not more than fourfold different in 
HI titres from the vaccine or reference viruses. 
Table 1
Viruses attributed to genetic and antigenic groupsa, weeks 40/2015–04/2016
Genetic group Number of viruses Antigenic group
Number of 
viruses
A(H1N1)pdm09 A/South Africa/3626/2013 (subgroup 6B)b 313 A(H1N1)pdm09 A/California/7/2009-like 379
A(H3N2) A/Hong Kong/4801/2014 (subgroup 3C.2a)b 50 A(H3N2) A/Hong Kong/4801/2014-like 6
A(H3N2) A/Samara/73/2013 (subgroup 3C.3)c 1 No separate antigenic category; expected to resemble A/Stockholm/28/2014 –
A(H3N2) A/Stockholm/28/2014 (subgroup 3C.3b)c 0 A(H3N2) A/ Stockholm/28/2014-like 0
A(H3N2) A/Switzerland/9715293/2013 (subgroup 3C.3a)b 26 A(H3N2) A/Switzerland/9715293/2013 14
B/Phuket/3073/2013 (Yamagata lineage clade 3)b 13 B/Phuket/3073/2013 (Yamagata lineage) -like 1
B/Brisbane/60/2008 (Victoria lineage clade 1A)d 44 B/Brisbane/60/2008 (Victoria lineage) -like 29
The viruses which were genetically characterised are not necessarily the same than the viruses that were antigenically characterised.
a Genetic and antigenic groups used for reporting into The European Surveillance System are defined by World Health Organization 
Collaborating Centre for Reference and Research on Influenza for each influenza season. For antigenic characterisation, to denote a virus 
isolate as being like a vaccine or reference virus its haemagglutination inhibition (HI) titre with post-infection ferret antiserum raised 
against the reference virus should differ by no more than fourfold. For genetic characterisation, the allocation to reporting category is 
based on the phylogenetic and amino acid sequence analyses of haemagglutinin (HA) gene.
b These genetic groups contain viruses with antigenic properties similar to the viruses included in the trivalent influenza vaccine for 2015/16.
c These genetic groups contain viruses with antigenic properties dissimilar to the viruses included in the trivalent influenza vaccine for 
2015/16.
d Viruses in this genetic group have antigenic properties similar to those of the vaccine component (B/Brisbane/60/2008) recommended for 
use in quadrivalent influenza vaccines for 2015/16.
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ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI685415 Netherlands A/Netherlands/2916/2015 6/11/2015
National Institute for Public 
Health and the Environment 
(RIVM)
National Institute for Public 
Health and the Environment 
(RIVM)
EPI674853 Sweden A/Stockholm/46/2015 9/10/2015 – Swedish Institute for Infectious Disease Control
EPI674745 Sweden A/Stockholm/47/2015 22/10/2015 – Swedish Institute for Infectious Disease Control
EPI674753 Sweden A/Stockholm/48/2015 24/10/2015 – Swedish Institute for Infectious Disease Control
EPI674841 Sweden A/Karlstad/4/2015 25/10/2015 – Swedish Institute for Infectious Disease Control
EPI674777 Sweden A/Stockholm/49/2015 7/11/2015 – Swedish Institute for Infectious Disease Control
EPI686820 Sweden A/Skovde/6/2015 18/11/2015 – Swedish Institute for Infectious Disease Control
EPI686772 Sweden A/Stockholm/ 57/2015 18/11/2015 – Swedish Institute for Infectious Disease Control
EPI674785 Sweden A/Stockholm/50/2015 11/11/2015 – Swedish Institute for Infectious Disease Control
EPI674793 Sweden A/Stockholm/51/2015 11/11/2015 – Swedish Institute for Infectious Disease Control
EPI674801 Sweden A/Stockholm/52/2015 11/11/2015 – Swedish Institute for Infectious Disease Control
EPI674847 Sweden A/Stockholm/53/2015 12/11/2015 – Swedish Institute for Infectious Disease Control
EPI674809 Sweden A/Stockholm/55/2015 10/11/2015 – Swedish Institute for Infectious Disease Control
EPI686764 Sweden A/Stockholm/56/2015 18/11/2015 – Swedish Institute for Infectious Disease Control
EPI686799 Sweden A/Stockholm/59/2015 19/11/2015 – Swedish Institute for Infectious Disease Control
EPI686828 Sweden A/Stockholm/60/2015 25/11/2015 – Swedish Institute for Infectious Disease Control
EPI686844 Sweden A/Stockholm/62/2015 26/11/2015 – Swedish Institute for Infectious Disease Control
EPI687173 Sweden A/Stockholm/66/2015 23/11/2015 – Swedish Institute for Infectious Disease Control
EPI687199 Sweden A/Stockholm/67/2015 21/11/2015 – Swedish Institute for Infectious Disease Control
EPI674825 Sweden A/Sweden/35/2015 12/11/2015 – Swedish Institute for Infectious Disease Control
EPI686852 Sweden A/Uppsala/8/2015 27/11/2015 – Swedish Institute for Infectious Disease Control
EPI686892 Sweden A/Sweden/37/2015 26/11/2015 – Swedish Institute for Infectious Disease Control
EPI686900 Sweden A/Sweden/38/2015 2/12/2015 – Swedish Institute for Infectious Disease Control
EPI686908 Sweden A/Sweden/39/2015 2/12/2015 – Swedish Institute for Infectious Disease Control
EPI694343 Sweden A/Uppsala/1/2016 11/1/2016 – Swedish Institute for Infectious Disease Control
EPI671518 Norway A/Norway/2625/2015 21/10/2015 Sorlandet Sykehus HF, Dept. of Medical Microbiology
Norwegian Institute of Public 
Health
EPI675750 Norway A/Norway/2659/2015 3/11/2015
Drammen Hospital / Vestreviken 
HF, Department for Medical 
Microbiology section Drammen
Norwegian Institute of Public 
Health
EPI675751 Norway A/Norway/2660/2015 3/11/2015
Drammen Hospital / Vestreviken 
HF, Department for Medical 
Microbiology section Drammen
Norwegian Institute of Public 
Health
Table 2a
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
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Table 2b
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI675754 Norway A/Norway/2672/2015 1/11/2015 Oslo University Hospital, Ulleval Hospital, Dept. of Microbiology
Norwegian Institute of Public 
Health
EPI675756 Norway A/Norway/2680/2015 12/11/2015 Ostfold Hospital - Fredrikstad, Dept. of Microbiology
Norwegian Institute of Public 
Health
EPI675760 Norway A/Norway/2687/2015 13/11/2015 – Norwegian Institute of Public Health
EPI695284 Norway A/Norway/2711/2015 18/11/2015 – Norwegian Institute of Public Health
EPI695299 Norway A/Norway/2914/2015 14/12/2015 Sorlandet Sykehus HF, Dept. of Medical Microbiology
Norwegian Institute of Public 
Health
EPI695310 Norway A/Norway/3004/2015 15/12/2015
Innlandet Hospital Trust, 
Division Lillehammer, 
Department for Microbiology
Norwegian Institute of Public 
Health
EPI695311 Norway A/Norway/3018/2015 26/12/2015 – Norwegian Institute of Public Health
EPI695313 Norway A/Norway/3038/2015 26/12/2015 Aalesund sjukehus Norwegian Institute of Public Health
EPI695343 Norway A/Norway/174/2016 7/1/2016 St. Olavs Hospital HF, Dept. of Medical Microbiology
Norwegian Institute of Public 
Health
EPI695344 Norway A/Norway/178/2016 6/1/2016 Health Forde, Department of Microbiology
Norwegian Institute of Public 
Health
EPI695349 Norway A/Norway/209/2016 8/1/2016 Stavanger Universitetssykehus, Avd. for Medisinsk Mikrobiologi
Norwegian Institute of Public 
Health
EPI677648 Finland A/Finland/541/2015 9/11/2015
Helsinki University Central 
Hospital, Laboratory Services 
(HUSLAB)
National Institute for Health and 
Welfare
EPI677651 Finland A/Finland/543/2015 19/11/2015
Helsinki University Central 
Hospital, Laboratory Services 
(HUSLAB)
National Institute for Health and 
Welfare
EPI678232 Finland A/Finland/544/2015 13/11/2015
Helsinki University Central 
Hospital, Laboratory Services 
(HUSLAB)
National Institute for Health and 
Welfare
EPI696158 Russia A/Tomsk/154/2015 19/11/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696470 Russia A/IIV-Moscow/211/2015 23/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696478 Russia A/IIV-Moscow/212/2015 23/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI690291 Spain A/Aragon/16005/2015 21/12/2015 Servicio de Microbiología Hospital Miguel Servet Instituto de Salud Carlos III
EPI671520 Norway A/Norway/2631/2015 26/10/2015 Sorlandet Sykehus HF, Dept. of Medical Microbiology
Norwegian Institute of Public 
Health
EPI671521 Norway A/Norway/2633/2015 27/10/2015 Haukeland University Hospital, Dept. of Microbiology
Norwegian Institute of Public 
Health
EPI671522 Norway A/Norway/2634/2015 27/10/2015 Haukeland University Hospital, Dept. of Microbiology
Norwegian Institute of Public 
Health
EPI671525 Norway A/Norway/2650/2015 3/11/2015 Ostfold Hospital - Fredrikstad, Dept. of Microbiology
Norwegian Institute of Public 
Health
EPI675748 Norway A/Norway/2651/2015 2/11/2015 Mikrobiologisk laboratorium, Sykehuset i Vestfold
Norwegian Institute of Public 
Health
EPI675749 Norway A/Norway/2658/2015 4/11/2015
Drammen Hospital / Vestreviken 
HF, Department for Medical 
Microbiology section Drammen
Norwegian Institute of Public 
Health
EPI695334 Norway A/Norway/139/2016 4/1/2016 Haukeland University Hospital, Dept. of Microbiology
Norwegian Institute of Public 
Health
EPI695336 Norway A/Norway/141/2016 4/1/2016 Unilabs Telelab, Laboratory for Medical Microbiology
Norwegian Institute of Public 
Health
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
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Table 2c
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI695339 Norway A/Norway/150/2016 12/1/2016 Stavanger Universitetssykehus, Avd. for Medisinsk Mikrobiologi
Norwegian Institute of Public 
Health
EPI695340 Norway A/Norway/151/2016 12/1/2016 Stavanger Universitetssykehus, Avd. for Medisinsk Mikrobiologi
Norwegian Institute of Public 
Health
EPI695287 Norway A/Norway/2734/2015 13/11/2015
Innlandet Hospital Trust, 
Division Lillehammer, 
Department for Microbiology
Norwegian Institute of Public 
Health
EPI695304 Norway A/Norway/2945/2015 16/12/2015 – Norwegian Institute of Public Health
EPI695314 Norway A/Norway/3039/2015 28/12/2015 Aalesund sjukehus Norwegian Institute of Public Health
EPI695326 Norway A/Norway/3114/2015 28/12/2015
Drammen Hospital / Vestreviken 
HF, Department for Medical 
Microbiology section Drammen
Norwegian Institute of Public 
Health
EPI678234 Finland A/Finland/545/2015 19/11/2015
Helsinki University Central 
Hospital, Laboratory Services 
(HUSLAB)
National Institute for Health and 
Welfare
EPI678238 Finland A/Finland/550/2015 4/12/2015 National Institute for Health and Welfare
National Institute for Health and 
Welfare
EPI678240 Finland A/Finland/553/2015 6/12/2015 NordLab Oulu National Institute for Health and Welfare
EPI693689 Finland A/Finland/556/2015 16/12/2015 National Institute for Health and Welfare
National Institute for Health and 
Welfare
EPI687734 Finland A/Finland/557/2015 15/12/2015 National Institute for Health and Welfare
National Institute for Health and 
Welfare
EPI693690 Finland A/Finland/558/2015 19/12/2015 National Institute for Health and Welfare
National Institute for Health and 
Welfare
EPI693691 Finland A/Finland/559/2015 14/12/2015 National Institute for Health and Welfare
National Institute for Health and 
Welfare
EPI693692 Finland A/Finland/560/2015 18/12/2015 National Institute for Health and Welfare
National Institute for Health and 
Welfare
EPI674284 Portugal A/Lisboa/31/2015 19/11/2015 Instituto Nacional de Saude INSA National Institute of Health Portugal
EPI674285 Portugal A/Lisboa/32/2015 18/11/2015 Instituto Nacional de Saude INSA National Institute of Health Portugal
EPI678690 Portugal A/Lisboa/33/2015 25/11/2015 Instituto Nacional de Saude INSA National Institute of Health Portugal
EPI678691 Portugal A/Lisboa/36/2015 2/12/2015 Instituto Nacional de Saude INSA National Institute of Health Portugal
EPI692997 Portugal A/Lisboa/53/2015 22/12/2015 Instituto Nacional de Saude INSA National Institute of Health Portugal
EPI678693 Portugal A/Lisboa/niSU82_15–16/2015 2/12/2015 Instituto Nacional de Saude INSA National Institute of Health Portugal
EPI699780 Greece A/Athens.GR/18/2016 4/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699778 Greece A/Athens.GR/19/2016 4/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699774 Greece A/Athens.GR/29/2016 7/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699772 Greece A/Athens.GR/38/2016 7/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699770 Greece A/Athens.GR/40/2016 7/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699766 Greece A/Athens.GR/54/2016 8/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699764 Greece A/Athens.GR/55/2016 8/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI670326 Romania A/Iasi/187166/2015 13/10/2015 Cantacuzino Institute Cantacuzino Institute
EPI690111 Romania A/Bucuresti/649-c7807/2015 22/12/2015 Cantacuzino Institute Cantacuzino Institute
EPI699023 Romania A/Bucuresti/190460/2016 19/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI696174 Russia A/IIV-Moscow/158/2015 12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
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Table 2d
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI696182 Russia A/IIV-Moscow/159/2015 12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696198 Russia A/IIV-Moscow/161/2015 14/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696246 Russia A/IIV-Moscow/169/2015 17/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696270 Russia A/IIV-Moscow/174/2015 16/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696278 Russia A/IIV-Moscow/176/2015 15/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696286 Russia A/IIV-Moscow/177/2015 16/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696326 Russia A/IIV-Moscow/183/2015 21/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696382 Russia A/IIV-Moscow/191/2015 20/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696414 Russia A/IIV-Moscow/195/2015 22/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI687093 Russia A/Saint-Petersburg/RII349/2015 25/11/2015 WHO National Influenza Centre Russian Federation
EPI696574 Russia A/Saint-Petersburg/RII350/2015 30/11/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696486 Russia A/Saint-Petersburg/RII01/2016 19/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696494 Russia A/Saint-Petersburg/RII02/2016 21/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696502 Russia A/Saint-Petersburg/RII03/2016 21/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696510 Russia A/Saint-Petersburg/RII04/2016 21/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696166 Russia A/IIV-Moscow/155/2015 7/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696518 Russia A/Saint-Petersburg/RII05/2016 14/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696526 Russia A/Saint-Petersburg/RII06/2016 14/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696534 Russia A/Saint-Petersburg/RII07/2016 21/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696542 Russia A/Saint-Petersburg/RII08/2016 22/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696558 Russia A/Saint-Petersburg/RII10/2016 23/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696566 Russia A/Saint-Petersburg/RII11/2016 24/12/2015 WHO National Influenza Centre Russian Federation
WHO National Influenza Centre 
Russian Federation
EPI696222 Russia A/IIV-Moscow/166/2015 16/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696238 Russia A/IIV-Moscow/168/2015 15/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
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Table 2e
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI696254 Russia A/IIV-Moscow/171/2015 17/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696294 Russia A/IIV-Moscow/178/2015 17/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696318 Russia A/IIV-Moscow/182/2015 18/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696334 Russia A/IIV-Moscow/185/2015 18/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696366 Russia A/IIV-Moscow/189/2015 19/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696374 Russia A/IIV-Moscow/190/2015 20/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696398 Russia A/IIV-Moscow/193/2015 21/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696406 Russia A/IIV-Moscow/194/2015 20/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696422 Russia A/IIV-Moscow/196/2015 22/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696430 Russia A/IIV-Moscow/199/2015 22/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696446 Russia A/IIV-Moscow/203/2015 22/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696454 Russia A/IIV-Moscow/204/2015 22/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI696462 Russia A/IIV-Moscow/208/2015 23/12/2015
D.I. Ivanovsky Research 
Institute of virology MoPH of 
RF,Moscow
WHO National Influenza Centre 
Russian Federation
EPI686526 Spain A/Madrid/1858/2015 22/12/2015 Servicio de Microbiología Hospital Ramón y Cajal Instituto de Salud Carlos III
EPI690296 Spain A/Madrid/1859/2015 23/12/2015 Servicio de Microbiología Hospital Ramón y Cajal Instituto de Salud Carlos III
EPI672780 Spain A/Madrid/SO13656/2015 21/10/2015 Instituto de Salud Carlos III Instituto de Salud Carlos III
EPI674599 Spain A/Madrid/SO13670/2015 20/10/2015 Instituto de Salud Carlos III Instituto de Salud Carlos III
EPI680490 Spain A/Madrid/SO13763/2015 8/12/2015 Instituto de Salud Carlos III Instituto de Salud Carlos III
EPI699957 Spain A/Madrid/41/2016 13/1/2016 Instituto de Salud Carlos III Instituto de Salud Carlos III
EPI699959 Spain A/Madrid/68/2016 12/1/2016 Servicio de Microbiología Hospital Ramón y Cajal Instituto de Salud Carlos III
EPI699960 Spain A/Madrid/69/2016 12/1/2016 Servicio de Microbiología Hospital Ramón y Cajal Instituto de Salud Carlos III
EPI690298 Spain A/Navarra/16004/2015 27/12/2015
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI686527 Spain A/Navarra/1829/2015 15/12/2015
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI686528 Spain A/Navarra/1850/2015 17/12/2015
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
10 www.eurosurveillance.org
Table 2f
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI690302 Spain A/Navarra/26/2016 3/1/2016
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI699967 Spain A/Navarra/50/2016 11/1/2016
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI699973 Spain A/Navarra/74/2016 14/1/2016
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI699974 Spain A/Navarra/75/2016 12/1/2016
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI699975 Spain A/Navarra/76/2016 14/1/2016
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI699977 Spain A/Navarra/78/2016 14/1/2016
Servicio de Microbiología 
Complejo Hospitalario de 
Navarra
Instituto de Salud Carlos III
EPI672781 Spain A/PaisVasco/1683/2015 21/10/2015 Servicio de Microbiología Hospital Donostia Instituto de Salud Carlos III
EPI686529 Spain A/PaisVasco/1844/2015 15/12/2015 Servicio de Microbiología Hospital Donostia Instituto de Salud Carlos III
EPI687827 Slovenia A/Slovenia/2903/2015 26/10/2015
Laboratory for Virology, 
National Institute of Public 
Health
Crick Worldwide Influenza 
Centre
KU558983 Czech Republic A/Czech Republic/95/2015 1/12/2015
National Institute of Public 
Health
National Institute of Public 
Health
EPI699832 Greece A/Athens.GR/2395/2015 23/12/2015 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699830 Greece A/Athens.GR/2407/2015 28/12/2015 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699827 Greece A/Athens.GR/2413/2015 29/12/2015 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI699824 Greece A/Athens.GR/12/2016 5/1/2016 Hellenic Pasteur Institute Hellenic Pasteur Institute
EPI698911 Romania A/Dambovita/190170/2016 18/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI698910 Romania A/Galati/190006/2016 8/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI699021 Romania A/Vrancea/190182/2016 18/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI699023 Romania A/Bucuresti/190324/2016 19/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI699059 Romania A/Bucuresti/190434/2016 23/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI698912 Romania A/Dambovita/190171/2016 18/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI699024 Romania A/Dambovita/190341/2016 21/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI699000 Romania A/Vrancea/190181/2016 11/1/2016 Cantacuzino Institute Cantacuzino Institute
EPI672779 Spain A/Aragon/1615/2015 29/9/2015 Servicio de Microbiología Hospital Miguel Servet Instituto de Salud Carlos III
EPI690293 Spain A/Asturias/1862/2015 17/12/2015
Servicio de Microbiología 
Hospital Central Universitario 
de Asturias
Instituto de Salud Carlos III
EPI699955 Spain A/Baleares/16036/2015 30/12/2015
Servicio de Microbiología 
Hospital Universitario Son 
Espases
Instituto de Salud Carlos III
EPI699956 Spain A/Baleares/35/2016 5/1/2016
Servicio de Microbiología 
Hospital Universitario Son 
Espases
Instituto de Salud Carlos III
EPI690295 Spain A/CastillaLaMancha/16013/2015 30/12/2015 Instituto de Salud Carlos III Instituto de Salud Carlos III
EPI624748 Russia A/St-Petersburg/122/2015 26/2/2015 WHO National Influenza Centre Russian Federation
Crick Worldwide Influenza 
Centre
EPI624673 Cameroon A/Cameroon/15V-3814/2015 7/5/2015 Centre Pasteur du Cameroun Crick Worldwide Influenza Centre
EPI624730 Norway A/Norway/1690/2015 17/3/2015 WHO National Influenza Centre Crick Worldwide Influenza Centre
11www.eurosurveillance.org
Table 2g
Details of the A(H1N1)pdm09 sequences retrieved from the Global Initiative on Sharing All Influenza Data (GISAID)’s 
EpiFlu Database or GenBank, for haemagglutinin-gene-based phylogenetic analysis in this study
ID: identity; SAR: Special Administrative Region; WHO: World Health Organization.
ID Country Strain name Collection date Originating laboratory Submitting laboratory
EPI630638 Mauritius A/Mauritius/I-463/2015 18/5/2015 Central Health Laboratory Crick Worldwide Influenza Centre
EPI621835 Madagascar A/Madagascar/1566/2015 15/4/2015 Institut Pasteur de Madagascar Crick Worldwide Influenza Centre
EPI630634 Hong Kong SAR A/Hong Kong/12243/2015 14/6/2015 Government Virus Unit
Crick Worldwide Influenza 
Centre
EPI630684 South Africa A/South Africa/R3723/2015 29/6/2015 Sandringham, National Institute for Communicable D
Crick Worldwide Influenza 
Centre
EPI630676 South Africa A/South Africa/R2977/2015 5/6/2015 Sandringham, National Institute for Communicable D
Crick Worldwide Influenza 
Centre
EPI630652 Slovenia A/Slovenia/1314/15 5/3/2015
Laboratory for Virology, 
National Institute of Public 
Health
Crick Worldwide Influenza 
Centre
EPI624706 Russia A/IIV-Moscow/94/2015 12/3/2015 Ivanovsky Research Institute of Virology RAMS
Crick Worldwide Influenza 
Centre
EPI624704 Russia A/IIV-Moscow/93/2015 10/3/2015 Ivanovsky Research Institute of Virology RAMS
Crick Worldwide Influenza 
Centre
EPI589565 Jordan A/Jordan/20241/2015 22/3/2015 Laboratory Directorate Crick Worldwide Influenza Centre
EPI253705 Germany A/Bayern/69/2009 1/1/2009 Robert-Koch-Institute Robert-Koch-Institute
EPI278607 New Zealand A/Christchurch/16/2010 12/7/2010 Canterbury Health Services
WHO Collaborating Centre for 
Reference and Research on 
Influenza
EPI319590 Russia A/Astrakhan/1/2011 28/2/2011 WHO National Influenza Centre Russian Federation
National Institute for Medical 
Research
EPI319527 Russia A/St. Petersburg/27/2011 14/2/2011 WHO National Influenza Centre Russian Federation
National Institute for Medical 
Research
EPI416411 Norway A/Norway/120/2013 2/1/2013 WHO National Influenza Centre National Institute for Medical Research
EPI574439 Ghana A/Ghana/DILI-14–0620/2014 7/7/2014 University of Ghana National Institute for Medical Research
EPI390473 Hong Kong SAR A/Hong Kong/5659/2012 21/5/2012 Government Virus Unit
National Institute for Medical 
Research
EPI326206 Hong Kong SAR A/Hong Kong/3934/2011 29/3/2011 Government Virus Unit
National Institute for Medical 
Research
EPI466626 South Africa A/South Africa/3626/2013 6/6/2013 Sandringham, National Institute for Communicable D
National Institute for Medical 
Research
EPI539472 Senegal A/Dakar/04/2014 3/2/2014 Institut Pasteur de Dakar National Institute for Medical Research
EPI417122 Senegal A/Dakar/20/2012 9/12/2012 Institut Pasteur de Dakar National Institute for Medical Research
EPI319447 Czech Republic A/Czech Republic/32/2011 18/1/2011
National Institute of Public 
Health
National Institute for Medical 
Research
EPI215957 Ukraine A/Lviv/N6/2009 27/10/2009 Ministry of Health of Ukraine National Institute for Medical Research
EPI320141 Russia A/St. Petersburg/100/2011 14/3/2011 Russian Academy of Medical Sciences
Centers for Disease Control and 
Prevention
EPI626148 Bangladesh A/Bangladesh/3003/2015 4/5/2015
Institute of Epidemiology 
Disease Control and Research 
(IEDCR) and Bangladesh 
National Influenza Centre (NIC)
Centers for Disease Control and 
Prevention
EPI626140 Bangladesh A/Bangladesh/01/2015 10/5/2015
Institute of Epidemiology 
Disease Control and Research 
(IEDCR) and Bangladesh 
National Influenza Centre (NIC)
Centers for Disease Control and 
Prevention
EPI176620 United States A/California/07/2009 9/4/2009 Naval Health Research Center
Centers for Disease Control and 
Prevention
EPI624468 French Guiana A/Guyane/1759/2015 9/4/2015 Institut Pasteur Institut Pasteur
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The data supporting the predominance of the 6B.1 
subclade stem from the subset of 12 European coun-
tries that reported virus characterisation data referring 
to sequences available in publically accessible data-
bases. These countries are well spread across Europe 
which corroborates the conclusion of widespread 6B.1 
subclade circulation. Data from the WHO Collaborating 
Centres indicate that the new subgroup remains 
antigenically similar to the vaccine component A/
California/7/2009 [1], but some recent A(H1N1)pdm09 
viruses within the 6B.1 and 6B.2 subclades reacted 
poorly with sera from individuals vaccinated with A/
California/7/2009-like-strain-containing vaccine [15]. 
The emergence of a new A(H1N1)pdm09 subclade may 
eventually affect the susceptibility of the population to 
the currently circulating A(H1N1)pdm09 viruses, e.g. by 
viruses drifting closer to become immune escape vari-
ants. It is not clear whether the emergence and predom-
inance of subclade 6B.1 has been driven by immune 
selection or what its impact on vaccine effectiveness 
may be and this needs assessment e.g. by generat-
ing lineage-specific estimation of vaccine effective-
ness. Early vaccine effectiveness estimates for A(H1N1)
pdm09 this season compared with the previous ones 
are not significantly different [16] from previous sea-
sons. As to the severity observed this season [1-4], 
similar observations have been made also in earlier 
seasons e.g. in 2010/11 in the United Kingdom, which 
experienced notably severe A(H1N1)pdm09 impact in 
the first post-pandemic season. 
Notably, recent studies have demonstrated that anti-
genic change in A(H1N1)pdm09 viruses is mainly 
caused by single amino acid substitutions affecting the 
loop located adjacent to the receptor binding site [17]; 
eight of the 215 analysed 2015/16 viruses possessed 
such substitutions, all six of the viruses in subclade 
6B.2 and two in 6B subgroup, that do not belong to any 
of the newly emerged subclades. 
Further enhancement of the antigenicity and virulence 
of influenza virus has been attributed to shielding of 
the major antigenic epitopes by alteration of N-linked 
glycosylation sites [18]. D127E substitution seen in 
6B.2 has been associated with antigenic change of 
other influenza viruses through modelling [17]. The 
change at position 173 (V173I) also in the 6B.2 sub-
clade of viruses is located in antigenic site Ca1 (posi-
tion 169–173), and therefore a change here could 
contribute to antigen drift. It has been proposed that 
the evolution of A(H1N1)pdm09 will involve the acquisi-
tion of additional glycosylations, as for former seasonal 
A(H1N1) HA [19]. Noteworthy, 80% of the analysed HA 
sequences have gained a potential glycosylation site 
S162N. No D222G/E/N substitutions were detected, 
nor N129D which was recently identified in India in two 
severe or fatal cases [9]. If the emerging groups con-
tinue to diversify from the vaccine component, their 
antigenic properties may change and the vaccine effec-
tiveness might be reduced. WHO recommended not to 
change the vaccine component of A(H1N1)pdm09 for 
the northern hemisphere 2016/17 season [20].
Early vaccine effectiveness estimates for 2015/16 are 
not yet available for A(H3N2) and B viruses which have 
been detected in lower numbers in most countries. 
The B/Victoria virus component is available only in the 
quadrivalent vaccines in the northern hemisphere for 
this season. As the majority of the countries use tri-
valent vaccines, the lineage switch from B/Yamagata 
to B/Victoria may contribute to lower vaccine effec-
tiveness against influenza B. For A(H3N2), the current 
component of influenza vaccines is expected to have 
improved vaccine effectiveness compared with the two 
previous seasons [21,22]. In the southern hemisphere, 
seasonal influenza vaccine has been demonstrated to 
have an overall effectiveness against A(H3N2) of 36% 
(95% confidence interval (CI): 11–54)) for general prac-
tice encounters and 50% (95%-CI: 20–68) for hospitali-
sations in 2015 [23]. Despite the changes in the genetic 
makeup of influenza A(H1N1)pdm09 viruses and the 
predominance of B/Victoria lineage over B/Yamagata 
lineage, seasonal influenza vaccine remains the single 
most effective measure to prevent severe outcomes of 
influenza.
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